US Treasury Mulls Limits on American Money Flowing into China’s Booming Biotech Scene

Washington’s finance chiefs are leaning into a debate that has been simmering for years: should American investors be allowed to pour money into China’s rapidly expanding biotech sector? A draft rule announced by the Treasury this week hints at stricter oversight, especially for companies that might be linked to the Chinese military or national security concerns.

In plain English, the proposal would make it harder for U.S. venture capital funds, pension plans, and even private equity houses to back Chinese drug developers without a more thorough vetting process. Critics argue that the move could stall collaboration on cutting‑edge therapies, while proponents say it’s a necessary safeguard against technology transfer that could advantage a potential geopolitical rival.

At the same time, a very different kind of biotech story is playing out on the other side of the Pacific. Telehealth platforms such as Quel, Livelyhood, and Choose Your Horizon have started prescribing GLP‑1 drugs—originally designed for diabetes and weight loss—to patients battling alcohol use disorder. The companies are doing it off‑label, meaning the FDA hasn’t officially signed off on this new use. Some are even offering compounded formulations that haven’t been reviewed by regulators.

“We see a gap in care for people who can’t access traditional addiction treatment,” says a spokesperson from Livelyhood. “GLP‑1s seem to blunt cravings and help with weight, which often goes hand‑in‑hand with substance use.” The approach is controversial, though; doctors worry about safety, dosage, and the ethics of prescribing a drug without FDA endorsement for a condition it wasn’t approved to treat.

Back on the corporate front, the hype machine is revving up for data from a late‑stage trial that pairs Moderna’s mRNA platform with Merck’s checkpoint inhibitor. Both companies are slated to present results at the upcoming European Society for Medical Oncology (ESMO) conference in Munich. If the vaccine‑plus‑immunotherapy combo shows a solid survival benefit in melanoma, it could be a game‑changer for oncology and a boon for shareholders.

Analysts are cautiously optimistic. “The science is sound, but the real test is whether the data hold up in a broader patient population,” notes a biotech equity analyst. “If it does, we could see a wave of similar combos across other hard‑to‑treat cancers.”

All these threads—government policy, telehealth innovation, and big‑ticket trial data—illustrate how biotech is now a crossroads of science, finance, and politics. Whether the Treasury’s possible restrictions will dampen cross‑border collaboration or simply shift investment to other regions remains to be seen. Meanwhile, patients and investors alike are watching closely as GLP‑1s find new, sometimes unapproved, roles and as pharma giants chase the next breakthrough at ESMO.